一 | The Hague, Oct 15 (UNI) Dutch Crown Princess Catharina-Amalia has moved from her student flat in Amsterdam to the royal palace for security reasons, King Willem-Alexander and Queen Maxima told Dutch media during their state visit to Sweden on Thursday.
"That has enormous consequences for her life. That means she doesn't live in Amsterdam and can't really go outside," Queen Maxima said.
King Willem-Alexander described the situation with his daughter as "very difficult." "I'm really proud of her for keeping it all up, to be honest," Queen Maxima said.
The 18-year-old crown princess moved to a student flat in Amsterdam to live and study last summer. Last month, newspaper De Telegraaf reported that security measures surrounding the princess had been significantly increased.
She and Prime Minister Mark Rutte allegedly appeared in organized crime communications, which may indicate plans for an attack or kidnapping.
The police and the public prosecution service made no further statements about the matter, but after the statements of the king and queen it is clear that the threat is serious and that it has a serious impact on the life of the princess.
"I can assure you that everyone is doing their utmost to ensure Amalia is safe," Justice and Security Minister Dilan Yesilgoz said in a statement. "I can't say anything about specific threats or specific security measures, but I guarantee that our security services are working hard day and night to ensure her safety."
UNI/XINHUA。 8月13日，钱塘生物医药产业再迎里程碑时刻。
二 | 位于杭州医药港的天境生物（TJ Biopharma）宣布，其产品注射用菲泽妥单抗（商品名：境斐®）正式获得国家药品监督管理局批准上市，用于与来那度胺和地塞米松联合用药，治疗既往至少接受过一线治疗的多发性骨髓瘤成年患者。这是该产品在全球范围内的首次获批。
三 | 境斐®是一款靶向CD38的人源单克隆抗体，由天境生物在中国完成了多发性骨髓瘤适应症的临床开发与注册申报。今年4月，该企业与全球生物制药巨头渤健达成战略合作，渤健获得该产品大中华区独家权益，交易总金额达8.5亿美元。这一合作也标志着渤健实现了菲泽妥单抗全球权益的统一。
四 | 根据协议，渤健将负责商业化，天境生物则依托其位于杭州医药港的GMP生产基地负责商业化供药。该基地已取得药品生产许可证，可实现核心产品的本土化稳定供应。“十年前，这些产品要等在国外上市了，再引进到中国重新做开发。目前，我们自主研发的产品把权益授权给海外公司。”天境生物董事长钱丽丽此前在接受央视《焦点访谈》采访时所说，从“引进来”到“授权出海”，钱塘创新药正完成角色的根本转换。境斐®的获批，也意味着今年以来钱塘已有3款1类创新药上市，数量位居全省第一。从“年年都有创新药”的目标提出，到如今多款产品密集落地，这一愿景正在钱塘一步步成为现实。
五 | 截至目前，杭州医药港已集聚生物医药企业1800余家，累计4款1类创新药获批上市。
六 | 另有138个创新药进入临床试验，数量居杭州市首位，其中14个药品处于临床三期。
Current article:http://6zb.shuicengchongmingnouhuawang.bond/2rz/20260826/7797546.html
Published on:14:41:45